Jublia (Topical application)

Jublia (Topical application) Uses, Dosage, Side Effects, Food Interaction and all others data.

Jublia (Topical application) is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

mean ± SD plasma Cmax on Day 28 of treatment: 0.67 ± 0.37 ng/mL.mean ± SD AUC was 12.15 ± 6.91 ng*h/mL.

Table Of contents

• Jublia (Topical application)
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Jublia (Topical application)
Generic	Efinaconazole
Efinaconazole Other Names	efinaconazol, Efinaconazole
Type
Formula	C18H22F2N4O
Weight	Average: 348.398 Monoisotopic: 348.17616767
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	USA
Last Updated:	September 19, 2023 at 7:00 am

Uses

Jublia (Topical application) is an antifungal agent used to treat onychomycosis, a fungal infection of the nail.

Indicated in the treatment of fungal infection of the nail, known as onychomycosis.

Jublia (Topical application) is also used to associated treatment for these conditions: Onychomycosis

How Jublia (Topical application) works

Jublia (Topical application) is an azole antifungal. Jublia (Topical application) inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes.

Food Interaction

No interactions found.

Half Life

29.9 hours in healthy patients.

Innovators Monograph

You find simplified version here Jublia (Topical application)